Hemostatic protein network

The hemostatic protein network refers to the integrated system of plasma proteins, such as fibrinogen, prothrombin, and von Willebrand factor, along with cellular components like platelets and erythrocytes, that collectively maintain vascular integrity and stop bleeding (ResearchGate, 2020). In a therapeutic context, this network is the target of various hemostatic agents that aim to accelerate or bypass the natural coagulation cascade to achieve rapid hemostasis (Journal of International Medical Research, 2008). For instance, the herbal mixture Ankaferd Blood Stopper (ABS) induces the near-instantaneous formation of a specific protein network and erythrocyte aggregation, primarily involving fibrinogen gamma, to create a mechanical barrier at the site of injury (ResearchGate, 2026). This mechanism is particularly useful in managing hemorrhages in patients with coagulopathies or those undergoing complex surgical procedures where traditional clotting mechanisms are impaired (ResearchGate, 2020). However, the manipulation of this network carries risks, including potential neurotoxicity and the danger of systemic thrombosis if the agents enter the circulation (ResearchGate, 2026).

Other names

Coagulation protein networkABS-induced protein networkErythroid-protein aggregation network

Induces the rapid formation of a physical protein-erythrocyte network by interacting with plasma proteins (primarily fibrinogen) and red blood cells, providing a scaffold for aggregation and mechanical sealing of injured vessels.